keyword
MENU ▼
Read by QxMD icon Read
search

Olmesartan enteropathy

keyword
https://www.readbyqxmd.com/read/27822952/sprue-like-enteropathy-associated-with-olmesartan-in-a-patient-with-villous-atrophy-hla-dq2-genotype-and-antinuclear-antibodies
#1
Isidro Machado, María Reolid, Fernando Martínez de Juan, Carmen Martínez Lapiedra, Fernanda Maia de Alcántara
We describe a new case of enteropathy with villous atrophy in a patient suffering from arterial hypertension treated with olmesartan. The molecular and serological studies showed anti-nuclear antibodies (ANA) and haplotype HLA-DQ2 positive, as well as negative results for anti-transglutaminase, anti-endomysium and anti-enterocytes antibodies. A duodenal villous atrophy was suspected by upper gastrointestinal endoscopy, which was confirmed by histopathology. The morphological picture was suggestive of sprue-like enteropathy with severe lymphoid infiltration and predominant T lymphoid cells...
November 2016: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/27803820/seronegative-intestinal-villous-atrophy-a-diagnostic-challenge
#2
Cláudio Martins, Cristina Teixeira, Suzane Ribeiro, Daniel Trabulo, Cláudia Cardoso, João Mangualde, Ricardo Freire, Ana Luísa Alves, Élia Gamito, Isabelle Cremers, Ana Paula Oliveira
Celiac disease is the most important cause of intestinal villous atrophy. Seronegative intestinal villous atrophy, including those that are nonresponsive to a gluten-free diet, is a diagnostic challenge. In these cases, before establishing the diagnosis of seronegative celiac disease, alternative etiologies of atrophic enteropathy should be considered. Recently, a new clinical entity responsible for seronegative villous atrophy was described-olmesartan-induced sprue-like enteropathy. Herein, we report two uncommon cases of atrophic enteropathy in patients with arterial hypertension under olmesartan, who presented with severe chronic diarrhea and significant involuntary weight loss...
2016: Case Reports in Gastrointestinal Medicine
https://www.readbyqxmd.com/read/27754281/hw-04-1-usefulness-of-big-data-in-clinical-research
#3
Rae Woong Park
Big data indicates the large and ever-increasing volumes of data adhere to the following 4Vs: volume (ever-increasing amount), velocity (quickly generated), variety (many different types), veracity (from trustable sources). The last decade has seen huge advances in the amount of data we routinely generate and collect in pretty much everything we do, as well as our ability to use technology to analyze and understand it. The routine operation of modern health care systems also produces an abundance of electronically stored data on an ongoing basis as a byproduct of clinical practice...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27643278/hw-04-1-usefulness-of-big-data-in-clinical-research
#4
Rae Woong Park
Big data indicates the large and ever-increasing volumes of data adhere to the following 4Vs: volume (ever-increasing amount), velocity (quickly generated), variety (many different types), veracity (from trustable sources). The last decade has seen huge advances in the amount of data we routinely generate and collect in pretty much everything we do, as well as our ability to use technology to analyze and understand it. The routine operation of modern health care systems also produces an abundance of electronically stored data on an ongoing basis as a byproduct of clinical practice...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27446852/duodenal-villous-atrophy-in-a-ttg-negative-patient-taking-olmesartan-a-case-report-and-review-of-the-literature
#5
Tasha Kulai, Thomas Arnason, Donald MacIntosh, John Igoe
Olmesartan, an angiotensin II receptor antagonist used to treat hypertension, is associated with few adverse effects. Here, a case of severe sprue-like enteropathy and acute kidney injury is described in a 68-year-old male taking olmesartan for 3-4 years. He presented to hospital with a five-week history of diarrhea, vomiting, and a 20 lb weight loss. Anti-TTG was negative with a normal IgA. Biopsies of the distal duodenum and duodenal cap revealed marked blunting of the villi with near complete villous atrophy of the biopsies from the bulb...
2016: Canadian Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27446843/adding-water-to-the-mill-olmesartan-induced-collagenous-sprue-a-case-report-and-brief-literature-review
#6
Claudine Desruisseaux, Michaël Bensoussan, Etienne Désilets, Hanh-Khiem Tran, Robert Arcand, Germain Poirier, Andrew Wisniewski, Thibaut Manière
Collagenous sprue (CS) is a distinct clinicopathological disorder histologically defined by a thickened subepithelial band (Freeman, 2011). It is a rare condition which has been recently observed in a significant proportion of sprue-like enteropathy associated with olmesartan, a novel entity described by Rubio-Tapia et al. in 2012. CS is historically associated with a poor prognosis (Marthey et al., 2014). However, histological and clinical improvements have been described in most studies with concomitant usage of corticosteroids and/or gluten-free diet (Marthey et al...
2016: Canadian Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27280200/olmesartan-sprue-like-enteropathy
#7
(no author information available yet)
A cohort study conducted in 2014, using data from France's mandatory health insurance system, has shown a 10-fold increased risk of hospitalisation for enteropathy with olmesartan in comparison with other ARBs (sartans) or ACE inhibitors. The increased incidence of enteropathy with olmesartan compared with other ARBs or ACE inhibitors is well documented. The French drug regulatory agency, ANSM, informed healthcare professionals of these risks in 2014. Yet prescription rates for olmesartan remain high, and new cases of olmesartan-associated enteropathy continue to be reported...
May 2016: Prescrire International
https://www.readbyqxmd.com/read/27129872/-enteropathy-due-to-olmesartan
#8
M Ould Sidi Mohamed, P Colardelle
The olmesartan is a selective antagonist of angiotensin II indicated for the treatment of essential hypertension. We report the case of a gastrointestinal involvement with duodenal villous atrophy and lymphocytic infiltrate duodenal epithelial and colonic secondary to the olmesartan taking with test of positive reintroduction. The patient had chronic diarrhea with weight loss of 10kg occurring one month after the passage of 20 to 40mg/day olmesartan took three years. A rectosigmoidoscopy highlighted some puncture slightly erythematous areas...
September 2016: Annales de Cardiologie et D'angéiologie
https://www.readbyqxmd.com/read/27109007/clinical-laboratory-serological-and-histological-profile-of-sprue-like-enteropathy-associated-with-olmesartan-use
#9
Esteban Sáez González, Francia Carolina Díaz Jaime, Adolfo Del Val Antoñana
Olmesartan is one of the various angiotensin II antagonists currently used for the management of high blood pressure. A sprue-like enteropathy was first described in 2012 in association with this antihypertensive drug. An observational, descriptive study was carried out on a series of 12 patients who met the clinical, histopathological, and outcome criteria for olmesartan-related sprue-like enteropathy from May 2013 to December 2015. All patients had watery diarrhea, weight loss, and negative celiac serology...
April 25, 2016: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/27099732/olmesartan-induced-enteropathy-associated-with-cutaneous-lesions
#10
Nassim Hammoudi, Marie Dior, Vincent Giraud, Benoit Coffin
Olmesartan is an angiotensin II receptor antagonist which may cause severe sprue-like enteropathy with duodenal villous atrophy. Skin lesions may be associated as reported for the first time in our case. Clinicians should be informed of this side effect and its reversibility after suspension of the drug.
April 2016: Clinical Case Reports
https://www.readbyqxmd.com/read/27001009/olmesartan-associated-sprue-like-enteropathy-know-your-enemy
#11
Gianluca Ianiro, Antonio Gasbarrini, Giovanni Cammarota
No abstract text is available yet for this article.
July 2016: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/26997446/olmesartan-associated-sprue-like-enteropathy-a-systematic-review-with-emphasis-on-histopathology
#12
REVIEW
Nina Burbure, Benjamin Lebwohl, Carolina Arguelles-Grande, Peter H R Green, Govind Bhagat, Stephen Lagana
Sprue-like enteropathy associated with the angiotensin II receptor blocker (ARB) olmesartan was first described in 2012, and a number of cases have since been reported. This syndrome is characterized by severe diarrhea and sprue-like histopathologic findings in the intestine, often with increased subepithelial collagen. The incidence of this adverse drug reaction is not entirely clear, although it is thought to be rare. It is also not well established if other ARBs cause such a syndrome, although case reports suggest they can...
April 2016: Human Pathology
https://www.readbyqxmd.com/read/26925975/sprue-like-enteropathy-linked-to-olmesartan
#13
Amaia Campos Ruiz, Leire Urtasun Arlegui, Carlos Marra-López Valenciano
Olmesartan is a therapy used for the management of hypertension available since 2002. A sprue like enteropathy associated with olmesartan has been first described in 2012. Endoscopic and histopathological findings are partial or total villous atrophy, mimicking a Celiac Disease. We explain two cases diagnosed in our hospital. Both patients took more than one year of treatment with olmesartan. In both cases, the biopsy showed duodenal villous atrophy, negative serology for celiac disease and they improved after stopping treatment with olmesartan...
May 2016: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/26699826/potential-coeliac-disease-markers-and-autoimmunity-in-olmesartan-induced-enteropathy-a-population-based-study
#14
Maria Esteve, Rocío Temiño, Anna Carrasco, Lissette Batista, Adolfo Del Val, Michel Blé, Santos Santaolaria, Javier Molina-Infante, Germán Soriano, Sandra Agudo, Yamile Zabana, Xavier Andújar, Montserrat Aceituno, Josepa Ribes, Rosa Madridejos, Fernando Fernández-Bañares
AIMS: (1) Assess the population-based incidence of severe olmesartan-associated enteropathy. (2) To describe patients of the Spanish registry. (3) Evaluate markers of potential coeliac disease and associated autoimmunity. METHODS: Crude incidence rates in the area of Terrassa (Catalonia) were calculated. Clinical characteristics of patients in the Spanish registry were collected. Duodenal lymphocyte subpopulations and anti-TG2 IgA deposits were assessed in a subset of patients...
February 2016: Digestive and Liver Disease
https://www.readbyqxmd.com/read/26571764/-case-report-olmesartan-associated-enteropathy-a-case-of-severe-watery-diarrhea-with-weight-loss-and-acute-renal-failure
#15
Tadashi Koizumi, Ken Furuya, Masaru Baba, Kuniaki Sadaoka, Chihiro Sekiya, Atsuo Hattori
No abstract text is available yet for this article.
June 10, 2015: Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine
https://www.readbyqxmd.com/read/26554620/an-emerging-issue-in-differential-diagnosis-of-diarrhea-sprue-like-enteropathy-associated-with-olmesartan
#16
LETTER
N Imperatore, R Tortora, P Capone, N Caporaso, A Rispo
No abstract text is available yet for this article.
March 2016: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/26437988/sprue-like-enteropathy-due-to-olmesartan
#17
LETTER
Cándido Muñoz-Muñoz, Josefa López-Vivancos, Walter Huaman, Montserrat García-Cors
A case of spue-like enteropathy due to olmesartan is reported to draw attention to this disease, given the high frequency of use of this drug and the difficulty of diagnosis if the entity if it is not known. In his journal one case was published as Clinical Note in 2014 and we wish to emphasize the importance of knowledge about this relatively new entity.
October 2015: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/26423313/immunopathogenesis-of-olmesartan-associated-enteropathy
#18
E V Marietta, A M Nadeau, A K Cartee, I Singh, A Rishi, R S Choung, T-T Wu, A Rubio-Tapia, J A Murray
BACKGROUND: Olmesartan-associated enteropathy (OAE) is characterised by diarrhoea, nausea, vomiting, abdominal pain, weight loss and severe sprue-like enteropathy, all of which are resolved after discontinuation of olmesartan medoximil. AIM: To determine the mechanistic similarities of OAE with coeliac sprue. METHODS: Duodenal biopsies were extracted from OAE patients before (n = 11) or after (n = 17) discontinuation of olmesartan medoxomil (on or off olmesartan medoxomil)...
December 2015: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/26414468/olmesartan-associated-enteropathy-a-review-of-clinical-and-histologic-findings
#19
REVIEW
Eun-Young Karen Choi, Barbara J McKenna
Olmesartan is an antihypertensive medication belonging to the angiotensin II receptor blocker class of drugs that has recently been associated with severe enteropathy. Olmesartan-associated enteropathy is uncommon and may be difficult to recognize because of its clinical and histologic similarities to other clinical entities, including celiac sprue and autoimmune enteropathy. The purpose of this article is to review the clinical and histologic findings of olmesartan-associated enteropathy that have been reported in the literature and to discuss clinical entities to consider in the differential diagnosis of olmesartan-associated enteropathy...
October 2015: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/26370634/an-atypical-case-of-chronic-diarrhoea-olmesartan-induced-sprue-like-enteropathy
#20
Dhaval K Naik, Matthew G Martelli, David Hernandez Gonzalo, Anil K Sharma, Davinderbir Pannu
Olmesartan use has been associated with chronic diarrhoea and weight loss due to severe sprue-like enteropathy, yet this is still not well known among clinicians. We present the unique case of an 84-year-old Filipino woman diagnosed with olmesartan-induced sprue-like enteropathy after an extensive work up for chronic diarrhoea, and without improvement despite multiple empiric treatments for nearly 15 months. Withdrawal of olmesartan resulted in clinical and histological improvement. This case provides further evidence for olmesartan-induced sprue-like enteropathy, and emphasises the importance of its awareness and recognition among gastroenterologists and primary care physicians alike...
2015: BMJ Case Reports
keyword
keyword
87609
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"